Preparing for and Managing Rare Diseases

PF header 2020

The advent of million-dollar therapies for rare diseases brings concerns for how managed care organizations (MCOs) will evaluate evidence, provide access and manage outcomes for these therapies in an environment of limited health care resources. This forum discussed the role of MCOs, life science companies, prescribers, patients, employers, and the government in supporting access to breakthrough therapies, identifying and managing these small but important populations of patients, and collecting real-world data on patient outcomes. This forum will identified key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.

Additional Materials:

Forum Program [PDF]
Press Release 
Executive Summary [PDF]
Forum Proceedings 
Pre-Forum Research Survey
Forum Webinar

PF Sept 2020

Related